Electromed Inc. (NYSEMKT:ELMD) was upgraded by equities researchers at TheStreet from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

Separately, Zacks Investment Research downgraded Electromed from a “hold” rating to a “sell” rating in a research note on Monday, September 12th.

Shares of Electromed (NYSEMKT:ELMD) opened at 4.43 on Friday. Electromed has a 12-month low of $1.55 and a 12-month high of $6.26. The firm’s 50-day moving average price is $4.73 and its 200 day moving average price is $4.40. The stock has a market capitalization of $36.40 million, a P/E ratio of 16.41 and a beta of 0.89.

Electromed (NYSEMKT:ELMD) last issued its earnings results on Tuesday, September 6th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by $0.01. The business earned $5.70 million during the quarter. Analysts predict that Electromed will post $0.19 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in Electromed during the first quarter valued at about $401,000. Bridgeway Capital Management Inc. increased its stake in Electromed by 800.0% in the second quarter. Bridgeway Capital Management Inc. now owns 90,000 shares of the company’s stock valued at $347,000 after buying an additional 80,000 shares during the period. Dimensional Fund Advisors LP increased its stake in Electromed by 121.3% in the second quarter. Dimensional Fund Advisors LP now owns 81,724 shares of the company’s stock valued at $315,000 after buying an additional 44,795 shares during the period. Eagle Global Advisors LLC bought a new stake in Electromed during the second quarter valued at about $134,000. Finally, Acrospire Investment Management LLC bought a new stake in Electromed during the first quarter valued at about $135,000.

About Electromed

Electromed, Inc, is a pharmaceutical company. The Company manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System (SmartVest System) includes its newest generation SmartVest SQL and previous generation SV2100 and related products, to patients with compromised pulmonary function.

Receive News & Ratings for Electromed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.